Abstract: A medical device has been disclosed. The medical device includes a parallel manipulator. The parallel manipulator having an end platform coupled to a surgical tool and a base platform coupled to machine module. The machine module is coupled to the surgical tool through a transmission shaft disposed between the end platform and the base platform.

Abstract: A surgical expandable implant includes a bolt, a movable member, and a support body. The bolt has a bolt body and a fixing member. The movable member is configured to be slidably sleeved on the bolt body. The support body has a first end configured to extend through the fixing member and a second end configured to extend through the movable member. The movable member is configured to slide along the length of the bolt body so as to move the support body from an initial shape to a deformed shape.

Abstract: A skin-care product includes a carrier, a middle pad, a protective film. The carrier has an attached surface and an engaging surface opposite to the attached surface. The attached surface is attached to an inner surface of an underwear. The middle pad is disposed on the engaging surface of the carrier and includes a maintenance ingredient for nourishing a human skin and has a contact surface. The protective film is engaged with the middle pad in a way that the protective film entirely covers the contact surface of the middle pad. The attached surface could be detachably connected to or fixed to the inner surface of the underwear. The protective film is removed before using the skin-care product, so that the contact surface of the middle pad could contact the human skin allow the user to do other housework or other activities while performing skincare, enhancing convenience.

Abstract: The invention provides a composition and pharmaceutical formulation including a peptide immobilized in a hydro gel. Compositions and formulations of the invention are useful in reducing the size, severity or duration of a wound, ameliorating of one or more symptoms associated with a wound without necessarily curing the wound, or lessening in the growth or severity of a wound. Compositions and formulations of the invention are particularly useful in the treatment of a wound associated with diabetes, such as a diabetic ulcer.

Abstract: This invention relates to porous perovskite photoactive films, and more particularly, to porous perovskite films containing microgels. The present invention also relates to processes for the preparation of these films and to their use in perovskite solar cells.

Abstract: Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): and/or a salt thereof, wherein R1 is —OH or —OP(O)(OH)2, and X1, X2, X3, R2, R2a, Ra, Rb, and Rc are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Abstract: Disclosed are compounds of Formula (I): (I) or a salt thereof, wherein: X is CH or N; Y is CH or N; R1 is —OH or —OP(O)(OH)2; L is —CR3?N—O—CRaRa— or CRaR—O—N?CR3; L2 is a bond, —C(O)—, or S(O)2—; and R2, R3, Ra, m, and n are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Abstract: Disclosed are compounds of Formula (I): (I) or a salt thereof, wherein: X is CH or N; Y is CH or N; R1 is —OH or —OP(O)(OH)2; L1 is —CR3?N—O—CRaRa— or CRaR—O—N?CR3; L2 is a bond, —C(O)—, or S(O)2—; and R2, R3, Ra, m, and n are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Abstract: There are described ROR? modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? Gamma activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? Gamma activity, for example, autoimmune and/or inflammatory disorders.

Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein: A is CR1 or N; B is CR3 or N; D is CR4 or N; L1 is —(CR7R7)m—; L2 is —(CR7R7)n—; and X, Z, R1, R2, R3, R4, R5, and R6 are define herein. Also disclosed are methods of using such compounds as modulators of TNF?, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

Abstract: Embodiments generally relate to systems, apparatus and methods concerned with autonomous preparation of brewed beverages, such as coffee beverages. Some embodiments make use of at least one robotic arm in the brewed beverage preparation. Various embodiments use two robotic arms. Various embodiments have multiple separately controlled components with which the at least one robotic arm can interact as part of the coffee preparation process.

Abstract: Disclosed are a low-fluorescence-photobleaching confocal imaging method and system. A confocal image is first selected as a reference image, and a threshold is set based on pixel values of the reference image. Then the density of fluorescent molecules in a pixel is determined based on a result of comparison of a real-time fluorescence intensity feedback and the threshold. Finally, an illumination time for the pixel is controlled based on the density of fluorescent molecules in the pixel to obtain a low-fluorescence-photobleaching confocal imaging image. The low-fluorescence-photobleaching confocal imaging method and system provided herein control the illumination time for each object-side pixel to make more efficient use of fluorescence information and reduce fluorescence photobleaching without sacrificing image quality, and so can be applied to a variety of biological samples. Further provided is a low-fluorescence-photobleaching confocal imaging system.

Abstract: A method and system for true product word recognition using a computing device. The method includes: obtaining title words from titles of products; determining word vectors based on a word matrix, where the word matrix is constructed based on a number of cooccurrence of each of the title words and all the other title words; determining title vectors based on a title matrix, where the title matrix is constructed based on the number of cooccurrence of each of the title words and all the other title words, and the title words in each of the titles; calculating scores for the title words in corresponding one of the titles based on the corresponding word vector and title vector; and recognizing true product words of the corresponding one of the titles based on the scores.

Abstract: Provided are an article processing method and apparatus, and a storage medium and an electronic device, relating to the technical field of data processing. The article processing method comprises: determining standard size information of various articles according to a standard size mapping relationship table; collecting article purchase information of a user, and extracting standard sizes corresponding to the various articles from the article purchase information and taking same as a target standard size set; determining user preference size information from the target standard size set according to the purchase times of the various articles; and querying articles corresponding to the user preference size information and outputting same as articles to be presented, and/or preferentially presenting the articles corresponding to the user preference size information.

Abstract: Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): and/or a salt thereof, wherein R1 is —OH or —OP(O)(OH)2, and X1, X2, X3, R2, R2a, Ra, Rb, and Rc are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Abstract: Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): and/or a salt thereof, wherein R1 is —OH or —OP(O)(OH)2, and X1, X2, X3, R2, R2a, Ra, Rb, and Rc are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Abstract: Disclosed are compounds of Formula (I), Formula (II), Formula (III), and Formula (IV) or salts thereof, wherein R2 is —OH or —OP(O)(OH)2; and R1 is defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.